Yoshiki Sawa

Japan stem cell oversight system too lax?

HeartSheet-Japan-system-stem-cell-oversight

The Japan stem cell and regenerative medicine oversight system has been designed to move investigational therapies forward fast, much faster than the systems in other countries such as the U.S. But how well is it working so far? It’s an important question both for that country and more globally as the Japanese system was touted …

Japan stem cell oversight system too lax? Read More »

Japan conditionally approves new IPS cell-based heart study

Yoshiki-Sawa-IPS-cells-stem-cells-heart-diseease

Where do things stand with IPS cell translational research? The newest development is that regulators in Japan just have given conditional approval to an Osaka University team to an induced pluripotent stem (IPS) cell-based study for ischemic heart disease. For years IPS cell-based products have been on-again off-again in active clinical study for macular degeneration, work …

Japan conditionally approves new IPS cell-based heart study Read More »